Evidence map›Paper›PMID 39511576›Full record

ArticleVirology journal2024

Pilot-scale process development for recombinant adeno-associated virus (rAAV) production based on high-density Sf9 cell culture.

Xinran Li, Jieyi Gu, Haoquan Wu, Yuanyuan Xie

Abstract read
In one paragraph

Article in Virology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xinran LiCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310000, China.
Jieyi GuKanglin Biotec (Hangzhou) Co., Ltd, Hangzhou, 310000, China.
Haoquan WuKanglin Biotec (Hangzhou) Co., Ltd, Hangzhou, 310000, China. wuhaoquan@kanglinbio.com.
Yuanyuan XieCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310000, China. xyycz@zjut.edu.cn.

Funding

Key Research and Development Program of Zhejiang Province 2021C03085
6 · The paper itself

Abstract

backgroundIn recent years, gene therapy drugs have been widely marketed, and their effectiveness and potential have been confirmed. Thus, increasing their production on an industrial scale is critical. Recombinant adeno-associated viruses (rAAVs) are optimal vectors for gene therapy applications, and the baculovirus expression vector system (BEVS), which is based on Sf9 cell culture, is a common tool for rAAV production.

methodsIn this work, an Sf9 cell fed-batch process was developed using shake flasks. In the laboratory-scale bioreactor, four processes were selected as the key factors when carrying out the orthogonal experiment. On the basis of the equal P/V principle and considering the problem posed by air bubbles, a pilot-scale level bioreactor process was established.

resultsHere, we describe a method in which a BEVS was used to produce rAAV vectors, with the cell density increasing to 22.8 × 10

conclusionsThis successful experiment not only provides a technological basis for further scale-up but also guarantees product capacity. We hope that this development process can provide reference data for studying cell culture-based drug production.

Indexed as

BioreactorsDependovirusGenetic VectorsVirus CultivationAnimalsBatch Cell Culture TechniquesCell Culture TechniquesPilot ProjectsSf9 CellsSpodopteraGene therapyProcess developmentrAAVScale-upSf9

Identifiers

PMID39511576
PMCPMC11542467

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.